These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33612460)

  • 1. Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy.
    Muhammad SD; Khan H; Hussain M; Zeb TF; Kumar D; Rahi R; Asif M; Balooch AA
    Pak J Pharm Sci; 2020 Jul; 33(4(Supplementary)):1771-1777. PubMed ID: 33612460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.
    Holstein A; Hahn M; Patzer O; Seeringer A; Kovacs P; Stingl J
    Eur J Clin Pharmacol; 2011 May; 67(5):471-6. PubMed ID: 21213107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.
    Yee J; Heo Y; Kim H; Yoon HY; Song G; Gwak HS
    Clin Ther; 2021 May; 43(5):836-843.e4. PubMed ID: 33840516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
    Saberi M; Ramazani Z; Rashidi H; Saberi A
    Vasc Health Risk Manag; 2020; 16():241-248. PubMed ID: 32606720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.
    Dujic T; Zhou K; Donnelly LA; Leese G; Palmer CNA; Pearson ER
    Diabetes Obes Metab; 2018 Jan; 20(1):211-214. PubMed ID: 28656666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups.
    Rabiee M; Marjani A; Khajeniazi S; Mojerloo M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):653-661. PubMed ID: 30129421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
    Klen J; Dolžan V; Janež A
    Eur J Clin Pharmacol; 2014 Apr; 70(4):421-8. PubMed ID: 24442125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Ragia G; Tavridou A; Petridis I; Manolopoulos VG
    Diabetes Res Clin Pract; 2012 Oct; 98(1):119-24. PubMed ID: 22591706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care.
    Mitchell SL; Leon DAC; Chaugai S; Kawai VK; Levinson RT; Wei WQ; Stein CM
    Pharmacogenomics J; 2020 Dec; 20(6):831-839. PubMed ID: 32504053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.
    Surendiran A; Pradhan SC; Agrawal A; Subrahmanyam DK; Rajan S; Anichavezhi D; Adithan C
    Eur J Clin Pharmacol; 2011 Aug; 67(8):797-801. PubMed ID: 21336994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
    Swen JJ; Wessels JA; Krabben A; Assendelft WJ; Guchelaar HJ
    Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.
    Lee HW; Lim MS; Lee J; Jegal MY; Kim DW; Lee WK; Jang IJ; Shin JG; Yoon YR
    J Clin Pharm Ther; 2012 Feb; 37(1):105-11. PubMed ID: 21208246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.
    Fokoun C; Serrier H; Rabier H; Goutelle S; Tod M; Bourguignon L
    Pharmacogenomics J; 2021 Oct; 21(5):559-565. PubMed ID: 33731883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes.
    Wang K; Yang A; Shi M; Tam CCH; Lau ESH; Fan B; Lim CKP; Lee HM; Kong APS; Luk AOY; Tomlinson B; Ma RCW; Chan JCN; Chow E
    Clin Pharmacol Ther; 2022 Feb; 111(2):461-469. PubMed ID: 34656068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.
    Kim NT; Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
    Arch Pharm Res; 2022 Feb; 45(2):114-121. PubMed ID: 34952963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.
    Mosikian A; Dolgorukova A; Zalevskaya A
    Pharmacogenomics; 2016 Dec; 17(18):2115-2126. PubMed ID: 27885968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.